Search research articles
Contact Us
Filters
Showing results (281-290 of 302) with videos related to
Page
of 31
Sort By:
Annals of Surgical Oncology
|
December 13, 2018
Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis
Elvire Pons-Tostivint, Youlia Kirova, Amélie Lusque, et al.
The New England Journal of Medicine
|
June 2, 2025
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
Mario Campone, Michelino De Laurentiis, Komal Jhaveri, et al.
JCO Precision Oncology
|
February 1, 2022
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations
David M Hyman, Ben Tran, Luis Paz-Ares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2016
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wolfgang Wick, Thierry Gorlia, Pierre Bady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2022
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer
Thomas Bachelot, Paul Cottu, Sylvie Chabaud, et al.
Nature
|
July 17, 2019
Author Correction: Genomic characterization of metastatic breast cancers
François Bertucci, Charlotte K Y Ng, Anne Patsouris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 6, 2024
Metabolomic Prediction of Breast Cancer Treatment-Induced Neurologic and Metabolic Toxicities
Max Piffoux, Jérémie Jacquemin, Mélanie Pétéra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2016
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova, Lecia V Sequist, Jose Manuel Perez Garcia, et al.
Cancer Treatment Reviews
|
October 6, 2022
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
Francesco Schettini, Sergio Venturini, Mario Giuliano, et al.
Journal of the National Cancer Institute
|
July 12, 2023
Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation
Félix Balazard, Aurélie Bertaut, Élise Bordet, et al.
Page
of 31
Search research articles
Search
Showing results (281-290 of 302) with videos related to
Sort By:
Page
of 31
Annals of Surgical Oncology
|
December 13, 2018
Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis
Elvire Pons-Tostivint, Youlia Kirova, Amélie Lusque, et al.
The New England Journal of Medicine
|
June 2, 2025
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
Mario Campone, Michelino De Laurentiis, Komal Jhaveri, et al.
JCO Precision Oncology
|
February 1, 2022
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations
David M Hyman, Ben Tran, Luis Paz-Ares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2016
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wolfgang Wick, Thierry Gorlia, Pierre Bady, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2022
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer
Thomas Bachelot, Paul Cottu, Sylvie Chabaud, et al.
Nature
|
July 17, 2019
Author Correction: Genomic characterization of metastatic breast cancers
François Bertucci, Charlotte K Y Ng, Anne Patsouris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 6, 2024
Metabolomic Prediction of Breast Cancer Treatment-Induced Neurologic and Metabolic Toxicities
Max Piffoux, Jérémie Jacquemin, Mélanie Pétéra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2016
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova, Lecia V Sequist, Jose Manuel Perez Garcia, et al.
Cancer Treatment Reviews
|
October 6, 2022
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
Francesco Schettini, Sergio Venturini, Mario Giuliano, et al.
Journal of the National Cancer Institute
|
July 12, 2023
Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation
Félix Balazard, Aurélie Bertaut, Élise Bordet, et al.
Page
of 31